Application of Solid Me<sub>3</sub>SiZnI for the Synthesis of Aryl and Alkyl Trimethylsilanes
作者:Anirban Ganguly、Revathi Chandrasekaran、Bala S. S. Balamurugan、Ramesh Rasappan
DOI:10.1002/adsc.202301298
日期:2024.3.19
group compatibility renders silylzinc reagents desirable; however, their development is hindered by their synthesis using pyrophoric silyllithium and dissolved lithium salts. Our solid Me3SiZnI circumvents these limitations and herein, we demonstrate its significance in the cross-coupling of aryl and alkyl bromides.
NOVEL CANCER TARGETING THERAPY USING COMPLEX OF SUBSTANCE CAPABLE OF BINDING SPECIFICALLY TO CONSTITUENT FACTOR OF CANCER STROMA AND ANTI-TUMOR COMPOUND
申请人:Japan Health Sciences Foundation
公开号:EP2359852A1
公开(公告)日:2011-08-24
The present invention is intended to provide a pharmaceutical for tumor treatment that stays specifically in interstitium for a long time and exhibits an effect, and provides a complex consisting of a substance having specific binding affinity for stroma and an antitumor compound bound to the substance via a linker.
N-(PIPERIDIN-4-YL)-4H-3,1-BENZO(THIA/OXA)ZINES-2-AMINES SUBSTITUEES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
申请人:PIERRE FABRE MEDICAMENT
公开号:EP1144408A1
公开(公告)日:2001-10-17
NOVEL CANCER TARGETING THERAPY USING COMPLEX OF SUBTANCE CAPABLE OF BINDING SPECIFICALLY TO CONSTITUENT FACTOR OF CANCER STROMA AND ANTI-TUMOR COMPOUND
申请人:Matsumura Yasuhiro
公开号:US20110287036A1
公开(公告)日:2011-11-24
The present invention is intended to provide a pharmaceutical for tumor treatment that stays specifically in interstitium for a long time and exhibits an effect, and provides a complex consisting of a substance having specific binding affinity for stroma and an antitumor compound bound to the substance via a linker.